Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) Posts Basic Consolidated EPS Of $-0.3995

0

Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP)managed to report annual basic consolidated EPS of $-0.3995, which was for the year ended2015-06-30.The company reported basic consolidated EPS of $-0.3995 for the quarter ended 2015-06-30.

EPS from continuing operations

If you look at the performance of the company’s continuing operations, you see that EPS generated from such operations was {EPS_BASIC_CONT_OPER:1541}} for the year ended 2015-06-30. As for the quarter ended 2015-06-30, continuing operations produced EPS of $-0.3121.

EPS contribution from parent

Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) received of $-0.3995 EPS boost from the parent company for the annual period ended

For the year ended 2015-06-30, the parent of Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) contributed EPS of $-0.3995 to the company’s bottom-line. But for the quarter ended 2015-06-30, EPS boost from the parent was cited as $-0.3995.

What About Basic net EPS

The basic net EPS that Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) reported for the year ended 2015-06-30 stood at $-0.3783. For the quarter ended 2015-06-30, the company posted basic net EPS of $-0.3783.

What About Consolidated Diluted EPS?

Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP)’s consolidated diluted EPS for the year ended 2015-06-30 was reported as $-0.3995. For the quarter ended 2015-06-30 the metric was$-0.3995.

Basic diluted EPS

The company managed to register diluted EPS from continuing operation of at $-0.3995 for the yearended 2015-06-30. But diluted EPS from continuing operations for the quarter ended 2015-06-30 came in at $-0.3995.

Net diluted EPS

Net diluted EPS posted by Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) for the year ended 2015-06-30 was $-0.3783. On quarterly basis, net diluted EPS for the quarter ended 2015-06-30 was reported as $-0.3783.

What portion of diluted EPS came from parent?

For the annual period ended 2015-06-30, the parent company of Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) said that it parent company boosted its diluted EPS by$-0.3995 in the year ended 2015-06-30. For the quarter ended 2015-06-30, the parent company’s contribution to diluted EPS was $-0.3995.

The company reported net basic EPS of $-0.42 for the year ended 2015-06-30 and net basic EPS of $-0.42 for the quarter ended 2015-06-30.

The number of Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP)’s basic shares outstanding at the end of the annual period ended 2015-06-30 was 54.169. That compares with 54.169 basic shares outstanding for the quarter ended 2015-06-30.

Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) had 54.169 diluted shares outstanding at the end of the annual period ended 2015-06-30. But for the quarter ended 2015-06-30, diluted outstanding shares were 54.169.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 19 times, 1 visits today)